P
Payal Kapur
Researcher at University of Texas Southwestern Medical Center
Publications - 244
Citations - 11224
Payal Kapur is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Clear cell renal cell carcinoma & Cancer. The author has an hindex of 42, co-authored 223 publications receiving 8743 citations. Previous affiliations of Payal Kapur include University of Texas at Dallas & University of California, Berkeley.
Papers
More filters
Journal ArticleDOI
845 irreversible electroporation: non-thermal and thermal capabilities for kidney ablation in a porcine model
Ephrem O. Olweny,Payal Kapur,Yung K. Tan,Samuel K. Park,Mehrad Adibi,Sara L. Best,Jeffrey A. Cadeddu +6 more
Journal ArticleDOI
1717 bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase-2 expression
Ramy F. Youssef,Payal Kapur,Wareef Kabbani,Shahrokh F. Shariat,Ahmed Mosbah,Hassan Abol-Enein,Mohamed Ghoniem,Yair Lotan +7 more
Journal ArticleDOI
Association of loss of BAP1 expression in cell renal cell carcinomas with PDL1 expression.
Richard W. Joseph,Payal Kapur,Daniel J. Serie,John C. Cheville,Jeanette E. Eckel-Passow,Mansi Parasramka,Thai H. Ho,Eugene D. Kwon,Robert Houston Thompson,James Brugarolas,Alexander S. Parker +10 more
TL;DR: A subset of clear cell renal cell carcinoma tumors evades the immune system through expression of programmed death ligand 1 (PDL1), and these tumors are associated with atypical granuloma-like tumors.
Journal ArticleDOI
1400 expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder
Ramy F. Youssef,Shahrokh F. Shariat,Payal Kapur,Wareef Kabbani,Tarek Ghoneim,Ellen King,Amber Cockburn,Ahmed Mosbah,Hassan Abol-Enein,Mohamed A. Ghoneim,Yair Lotan +10 more
TL;DR: Elevated renal venous pressure-induced bleeding from locally ruptured minute vessels in the renal calyces was considered as a cause of chronic unilateral hematuria.
Proceedings ArticleDOI
Abstract 4106: Outcomes of combined ipilimumab and nivolumab therapy following progression on nivolumab monotherapy in renal cell carcinoma: A retrospective cohort study
Roy Elias,Nirmish Singla,Isaac Bowman,Payal Kapur,Raquibul Hannan,Hans J. Hammers,James Brugarolas +6 more
TL;DR: In this analysis, Ipi/Nivo did not confer substantial treatment benefit to patients who had already progressed on Nivo alone, suggesting that alternative agents, such as TKIs, remain effective treatments in this population.